 Colorectal cancer, CRC, is a major health concern worldwide with few effective treatments available. Ruthenium compounds are showing promise as a new class of anti-cancer agents with particular efficacy against CRC cells. These compounds have been found to reduce cell growth, induce apoptosis, and disrupt the cytoskeletal structure of CRC cells. Additionally, they have been shown to modulate the expression of proteins involved in cellular processes such as oxidative stress and mitochondrial function. This article was authored by Ana Rita Braz, Pedro Fernandez, Thiago Morera, and others.